ACELYRIN to Announce Q2 2024 Financial Results and Update on August 13, 2024

LOS ANGELES, Aug. 06, 2024 -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company specializing in the rapid development and delivery of significant immunological treatments, has announced it will conduct a conference call on Tuesday, August 13, 2024, at 5:00 p.m. ET to review its financial performance for the second quarter of 2024 and discuss the company's ongoing projects. The conference call will be streamed live on the company’s website under the Events & Presentations section, and a replay will be available for 90 days post-event.

ACELYRIN, INC. is a biopharma company based in the Los Angeles area with additional operations in the San Francisco Bay area. The company is committed to offering life-changing treatment options by focusing on the identification, acquisition, and acceleration of transformative medicines' development and commercialization. ACELYRIN is currently advancing two major programs in its late-stage clinical pipeline.

The first program includes Lonigutamab, a subcutaneously administered monoclonal antibody that targets IGF-1R, which is moving into Phase 2b/3 clinical development for treating thyroid eye disease. The second program is Izokibep, a next-generation IL-17A inhibitor, which is in Phase 2b/3 development for treating psoriatic arthritis, hidradenitis suppurativa, and uveitis. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!